Crescent Biopharma, Inc. reported significant financial developments in its latest 10-Q filing for the quarter ending September 30, 2025. The company, which focuses on developing novel therapeutics for solid tumors, recorded a net loss of $24.6 million for the third quarter and $61.5 million for the nine months ended September 30, 2025. This marks a substantial increase in losses compared to the $2.6 million loss reported for the period from September 19, 2024, its inception, through September 30, 2024. The increase in losses is attributed primarily to heightened research and development expenses, which totaled $20.3 million for the quarter and $43.1 million for the nine-month period, reflecting a significant investment in its lead program, CR-001, and other development activities.
Crescent Biopharma's total operating expenses for the third quarter reached $25.9 million, a sharp rise from just $2.6 million in the prior year period. The company has not yet generated any revenue from product sales, as it remains in the preclinical stage of development. As of September 30, 2025, Crescent Biopharma had cash and cash equivalents of $133.3 million, a substantial increase from $34.8 million at the end of 2024, primarily due to a successful pre-closing financing that raised approximately $143 million. This capital is expected to support the company's operations for at least the next twelve months.
Strategically, Crescent Biopharma has made significant strides, including the completion of a reverse recapitalization with GlycoMimetics, Inc. on June 13, 2025. This merger has positioned Crescent to leverage GlycoMimetics' existing resources while focusing on its proprietary anti-PD-1/anti-VEGF bispecific antibody, CR-001. The company has also entered into licensing agreements with Paragon Therapeutics for its product candidates, which include CR-001 and CR-002, further solidifying its development pipeline.
Operationally, Crescent Biopharma is actively engaged in advancing its research programs, with a focus on CR-001, which is designed to improve clinical efficacy and safety compared to existing treatments. The company plans to submit an Investigational New Drug application for CR-001 by the end of 2025, with initial clinical data expected in the second half of 2026. The company has also exercised options for additional product candidates, CR-002 and CR-003, under agreements with Paragon, indicating a commitment to expanding its therapeutic offerings.
Looking ahead, Crescent Biopharma anticipates continued investment in research and development, with expectations of increased operating expenses as it progresses through clinical trials. The company acknowledges the inherent risks associated with drug development and regulatory approval processes, which could impact its financial performance and operational plans. However, with a robust cash position and strategic partnerships, Crescent Biopharma is positioned to advance its clinical programs and potentially generate revenue in the future.
About CRESCENT BIOPHARMA, INC.
GlycoMimetics, Inc. is a biotechnology company specializing in glycomimetic small molecules that target carbohydrate-related biological processes. Its focus includes developing therapies for cancers and inflammatory diseases, with a pipeline centered on selectin antagonists like uproleselan. The company collaborates globally, holds key patents, and relies on third-party manufacturing, aiming to address high unmet medical needs through innovative, proprietary drug candidates.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.